Buprenorphine Maintenance for Opioid Addicts - 2

This study has been completed.

First Received on September 20, 1999. Last Updated on August 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000203

Purpose

The purpose of this study is to evaluate varying doses of buprenorphine for opioid dependence and cocaine abuse.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Buprenorphine	Phase II

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Buprenorphine Maintenance for Opioid Addicts

Resource links provided by NLM:

Drug Information available for: Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Withdrawal symptoms
Psychological symptoms

Estimated Enrollment:

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000203

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators

Principal Investigator:

Thomas R Kosten, M.D.

VA Connecticut Healthcare System

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000203 History of Changes
Other Study ID Numbers:	NIDA-05626-2, R01-05626-2
Study First Received:	September 20, 1999
Last Updated:	August 23, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Opioid-Related Disorders
Substance-Related Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotic Antagonists
Narcotics

ClinicalTrials.gov processed this record on February 09, 2012